30
Participants
Start Date
May 1, 2025
Primary Completion Date
December 31, 2026
Study Completion Date
March 31, 2027
semaglutide or tirzepatide
Semaglutide and tirzepatide will be dosed as per prescription labels
Lifestyle modification intervention
All participants will be recommended the following: 1) low-calorie diet based on their predicted by Harris Benedict resting energy expenditure minus 500 kcal per day; 2) physical activity: a goal of 10,000 steps or more per day; 3) exercise: a goal of 150 minutes or more of moderate-intensity aerobic activity (cardiovascular exercise) per week; 4) limited consumption of liquid calories (i.e. sodas, juices, alcohol, etc.).
Mayo Clinic in Florida, Jacksonville
Lead Sponsor
Mayo Clinic
OTHER